Biorecognizable Nanoparticles Based On Hyaluronic Acid/Poly(ε-Caprolactone) Block Copolymer

Authors: Jong Ho Hwang, Dae Hwan Kang, Young-IL Jeong

Abstract:

Since hyaluronic acid (HA) receptor such as CD44 is over-expressed at sites of cancer cells, HA can be used as a targeting vehicles for anti-cancer drugs. The aim of this study is to synthesize block copolymer composed of hyaluronic acid and poly(ε-caprolactone) (HAPCL) and to fabricate polymeric micelles for anticancer drug targeting against CD44 receptor of tumor cells. Chemical composition of HAPCL was confirmed using 1H NMR spectroscopy. Doxorubicin (DOX) was incorporated into polymeric micelles of HAPCL. The diameters of HAPHS polymeric micelles were changed around 80nm and have spherical shapes. Targeting potential was investigated using CD44-overexpressing. When DOX-incorporated polymeric micelles was added to KB cells, they revealed strong red fluorescence color while blocking of CD44 receptor by pretreatment of free HA resulted in reduced intensity, indicating that HAPCL polymeric micelles have targetability against CD44 receptor.

Keywords: Hyaluronic acid, CD44 receptor, biorecognizable nanoparticles, block copolymer.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1087285

References:

[1] X. Huang, Y.I. Jeong, B.K. Moon, L. Zhang, D.H. Kang, I. Kim, "Self-assembly of morphology-tunable architectures from tetraarylmethane derivatives for targeted drug delivery," Langmuir, vol. 29, no. 10, pp. 3223-3333, 2013.
[2] S. Xu, Q. Xu, J. Zhou, J. Wang, N. Zhang, L. Zhang, "Preparation and characterization of folate-chitosan-gemcitabine core-shell nanoparticles for potential tumor-targeted drug delivery," J Nanosci. Nanotechnol. vol. 13, no. 1, pp. 129-138, 2013.
[3] Y. Bae, W.D. Jang, N. Nishiyama, S. Fukushima, K. Kataoka. "Multifunctional polymeric micelles with folate-mediated cancer cell targeting and pH-triggered drug releasing properties for active intracellular drug delivery," Mol. Biosyst. vol. 1, no. 3, pp. 242-250, 2005.
[4] V. Ladeda, J.A. Aguirre Ghiso, E. Bal de Kier Joffe, "Function and expression of CD44 during spreading, migration, and invasion of murine carcinoma cells," Exp. Cell Res., vol. 242, pp. 515-527, 1998.
[5] Y. Akiyama, S. Jung, B. Salhia, S. Lee, S. Hubbard, M. Taylor, T. Mainprize, K. Akaishi, W. Furth, J. T. Rutka, "Hyaluronate receptors mediating glioma cell migration and proliferation," J. Neuro-Oncol., vol. 53, pp. 115–127, 2001.
[6] E. Auzenne, S.C. Ghosh, M. Khodadadian, B. Rivera, D. Farquhar, R.E. Price, M. Ravoori, V. Kundra, R.S. Freedman, J. Klostergaard, "Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts," Neoplasia, vol. 9, pp. 479-486, 2007.
[7] N. Senzer, J. Nemunaitis, D. Nemunaitis, C. Bedell, G. Edelman, M. Barve, R. Nunan, K. F. Pirollo, A. Rait, E.H. Chang, "Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors," Mol Ther. vol. 21, no. 5, pp. 1096-1103, 2013.
[8] Y.I. Jeong, D.H. Kim, C.W. Chung, J.J. Yoo, K.H. Choi, C.H. Kim, S.H. Ha, D.H. Kang, "Self-assembled nanoparticles of hyaluronic acid/poly(DL-lactide-co-glycolide) block copolymer," Colloids Surf B Biointerfaces. vol. 90, pp. 28-35, 2012.
[9] Y. Luo, G.D. Prestwich, "Synthesis and selective cytotoxicity of a hyaluronic acid–antitumor bioconjugate," Bioconj. Chem., vol. 10, pp. 755–763, 1999.
[10] Y. Luo, N.J. Bernshaw, Z.R. Lu, J. Kopecek, G.D. Prestwich, "Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates," Pharm. Res., vol. 19, pp. 396-402, 2002.
[11] E. Segawa, H. Kishimoto, K. Takaoka, K. Noguchi, S. Hashitani, K. Sakurai, M. Urade, "Promotion of hematogenous metastatic potentials in human KB carcinoma cells with overexpression of cyclooxygenase-2," Oncol. Rep. vol. 24, no. 3, pp. 733-739, 2010.